5 hours ago 1

Regeneron Pharmaceuticals to Acquire 23andMe for $256M

Ahad Tariq

Mon, May 19, 2025, 8:28 AM 1 min read

23andMe had filed for bankruptcy protection in March this year, while REGN was the sole bidder for its assets. REGN intends to acquire its Personal Genome Service, Total Health, and Research Services business line, together with its Biobank and associated assets, but does not include its Lemonaid Health subsidiary.

Regeneron Pharmaceuticals to acquire 23andMe for $256M

A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality.

The deal is subject to bankruptcy court and regulatory approvals and other customary closing conditions, with the deal expected to close by the third quarter of 2025. 23andMe will be solely owned and operated by Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Co-Founder, Board Co-Chair, President and Chief Scientific Officer of Regeneron, George D. Yancopoulos, M.D. Ph.D., stated:

“Regeneron was one of the first biotech companies to bet its future on the power of DNA, fueling our drug discovery efforts so as to deliver some of the world’s leading and most innovative medicines, including treatments to prevent blindness, for allergic diseases from asthma to atopic dermatitis, for several forms of cancer, and even for Ebola and COVID-19”.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.